JP2009536191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536191A5 JP2009536191A5 JP2009508544A JP2009508544A JP2009536191A5 JP 2009536191 A5 JP2009536191 A5 JP 2009536191A5 JP 2009508544 A JP2009508544 A JP 2009508544A JP 2009508544 A JP2009508544 A JP 2009508544A JP 2009536191 A5 JP2009536191 A5 JP 2009536191A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- formula
- patient
- cell proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 238000000034 method Methods 0.000 claims 13
- 208000035269 cancer or benign tumor Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000002889 endothelial cell Anatomy 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 244000144972 livestock Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 0 CC1(*)C=CC(CCC(NC(Cc2ccccc2)*[Zn])=O)=CC=C1 Chemical compound CC1(*)C=CC(CCC(NC(Cc2ccccc2)*[Zn])=O)=CC=C1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79910306P | 2006-05-09 | 2006-05-09 | |
| US60/799,103 | 2006-05-09 | ||
| PCT/IB2007/002471 WO2007129226A2 (en) | 2006-05-09 | 2007-05-09 | Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009536191A JP2009536191A (ja) | 2009-10-08 |
| JP2009536191A5 true JP2009536191A5 (enExample) | 2011-09-08 |
| JP5225264B2 JP5225264B2 (ja) | 2013-07-03 |
Family
ID=38668152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009508544A Expired - Fee Related JP5225264B2 (ja) | 2006-05-09 | 2007-05-09 | 細胞増殖障害の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20090306214A1 (enExample) |
| EP (1) | EP2026775B1 (enExample) |
| JP (1) | JP5225264B2 (enExample) |
| AU (1) | AU2007246779B2 (enExample) |
| CA (1) | CA2651375C (enExample) |
| DK (1) | DK2026775T3 (enExample) |
| ES (1) | ES2542344T3 (enExample) |
| HU (1) | HUE026820T2 (enExample) |
| IL (1) | IL195152A (enExample) |
| PL (1) | PL2026775T3 (enExample) |
| PT (1) | PT2026775E (enExample) |
| WO (1) | WO2007129226A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031129A2 (en) * | 2002-10-03 | 2004-04-15 | New Era Biotech, Ltd. | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| CA2560922C (en) * | 2004-03-26 | 2014-01-07 | New Era Biotech, Ltd. | Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions |
| GB0804213D0 (en) * | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| PL2475361T3 (pl) * | 2009-09-09 | 2020-07-13 | Novaremed Ltd. | N-podstawione benzenopropanoamidy do stosowania w leczeniu bólu i stanu zapalnego |
| US8802734B2 (en) | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| ES2834638T3 (es) | 2013-05-30 | 2021-06-18 | Infinity Pharmaceuticals Inc | Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| PE20160685A1 (es) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| MX391135B (es) | 2016-06-24 | 2025-03-21 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12605387B2 (en) | 2020-07-24 | 2026-04-21 | Secura Bio, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1908322A (en) * | 1932-04-07 | 1933-05-09 | Claude R Cook | Weed puller |
| US2908691A (en) * | 1958-07-14 | 1959-10-13 | Searle & Co | Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2004031129A2 (en) * | 2002-10-03 | 2004-04-15 | New Era Biotech, Ltd. | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| CA2560922C (en) * | 2004-03-26 | 2014-01-07 | New Era Biotech, Ltd. | Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions |
-
2007
- 2007-05-09 AU AU2007246779A patent/AU2007246779B2/en not_active Ceased
- 2007-05-09 WO PCT/IB2007/002471 patent/WO2007129226A2/en not_active Ceased
- 2007-05-09 DK DK07804842.8T patent/DK2026775T3/en active
- 2007-05-09 EP EP07804842.8A patent/EP2026775B1/en not_active Not-in-force
- 2007-05-09 CA CA2651375A patent/CA2651375C/en not_active Expired - Fee Related
- 2007-05-09 JP JP2009508544A patent/JP5225264B2/ja not_active Expired - Fee Related
- 2007-05-09 ES ES07804842.8T patent/ES2542344T3/es active Active
- 2007-05-09 PT PT78048428T patent/PT2026775E/pt unknown
- 2007-05-09 HU HUE07804842A patent/HUE026820T2/en unknown
- 2007-05-09 US US12/227,104 patent/US20090306214A1/en not_active Abandoned
- 2007-05-09 PL PL07804842T patent/PL2026775T3/pl unknown
-
2008
- 2008-11-06 IL IL195152A patent/IL195152A/en active IP Right Grant
-
2012
- 2012-01-06 US US13/344,976 patent/US20120108666A1/en not_active Abandoned
-
2013
- 2013-10-09 US US14/049,454 patent/US20140039060A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540555A5 (enExample) | ||
| CA2651375A1 (en) | Treatment of cell proliferative disorders | |
| JP2009543860A5 (enExample) | ||
| JP2012506872A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| JP2008531604A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2010540556A5 (enExample) | ||
| JP2011046708A5 (enExample) | ||
| JP2008539267A5 (enExample) | ||
| JP2012523395A5 (enExample) | ||
| JP2015522589A5 (enExample) | ||
| JP2012522841A5 (enExample) | ||
| JP2017503753A5 (enExample) | ||
| JP2007502832A5 (enExample) | ||
| JP2013537240A5 (enExample) | ||
| RU2012150501A (ru) | Противораковые стероидные лактоны, ненасыщенные в положении 7(8) | |
| JP2009502777A5 (enExample) | ||
| JP2012505905A5 (enExample) | ||
| JP2014511897A5 (enExample) | ||
| JP5289310B2 (ja) | 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤 | |
| JP2010500284A5 (enExample) |